News & Updates

Show Multimedia Only
Enzalutamide edges out abiraterone in mCRPC

Enzalutamide edges out abiraterone in mCRPC

15 Sep 2024 byJairia Dela Cruz

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.

Enzalutamide edges out abiraterone in mCRPC

15 Sep 2024
Rezum boosts sexual function in men with or without ED

Rezum boosts sexual function in men with or without ED

13 Sep 2024

Treatment with Rezum improves sexual function in men with baseline erectile dysfunction (ED) and maintains long-term sexual function in those without ED, reports a study. However, men with ED may go through temporary decline in sexual function at 1 year.

Rezum boosts sexual function in men with or without ED

13 Sep 2024
Tadalafil helps recover erectile function in young men with ED

Tadalafil helps recover erectile function in young men with ED

18 Aug 2024 byStephen Padilla

Nearly one in two young men with primary psychogenic erectile dysfunction (ED) treated with tadalafil 5 mg once daily achieve spontaneous medication-free erectile function (EF) at 3 months, as shown in a study. Younger patients tend to have a higher chance of recovery after drug discontinuation.

Tadalafil helps recover erectile function in young men with ED

18 Aug 2024
AI improves physician accuracy in identifying prostate cancer extent

AI improves physician accuracy in identifying prostate cancer extent

16 Aug 2024